Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7

This study has been completed.

First Received: September 20, 1999 Last Updated: June 23, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	University of Pennsylvania
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000358

Purpose

The purpose of this study is to determine the safety of lofexidine in the treatment of opiate withdrawal. Preliminary data will also be obtained to assess the ability of lofexidine to alleviate opiate withdrawal signs and symptoms.

Condition	Intervention	Phase
Opioid-Related Disorders Substance-Related Disorders	Drug: Lofexidine	Phase I

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Safety Evaluation of Lofexidine for Treatment of Opioid Withdrawal

Resource links provided by NLM:

Drug Information available for: Lofexidine hydrochloride Lofexidine

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Estimated Enrollment:

Eligibility

Ages Eligible for Study:	21 Years to 59 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000358

Locations

United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

University of Pennsylvania

Investigators

Principal Investigator:

Charles O'Brien, M.D., Ph.D.

PDVAMC Treatment Research Center

More Information

No publications provided

Study ID Numbers:	NIDA-3-0012-7, Y01-3-0012-7
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000358 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Neurotransmitter Agents
Disease
Adrenergic alpha-Agonists
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Narcotic Antagonists
Physiological Effects of Drugs
Disorders of Environmental Origin
Cardiovascular Agents
Opioid-Related Disorders
Lofexidine

Antihypertensive Agents
Pharmacologic Actions
Adrenergic Agonists
Pathologic Processes
Sensory System Agents
Mental Disorders
Therapeutic Uses
Substance-Related Disorders
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on November 27, 2009